Avantium provides Crystal 16TM to all research sites of Sanofi-Aventis

Avantium Technologies has announced an agreement with Sanofi-Aventis for the deployment of its proprietary Crystal16™ at all R&D centres of Sanofi-Aventis.

Sanofi-Aventis has selected the Crystal16™:
- for the enhancement of its crystallisation research capabilities
- to increase the experimental throughput of its scientists
- to perform crystallisation experiments on a smaller scale

The Crystal16™ is a novel and proprietary platform that can be used for a range of applications in pharmaceutical and chemical research.

Users of the Crystal16™ are capable of running 16 experiments in parallel retrieving maximum knowledge about the crystallisation process and solid-state of their product.

Avantium International B.V.

Avantium International B.V.
R&D services


DownloadFull Press Release

Latest News

Clinical study supports the use of Cheetah Medical's technologies

Cheetah Medical, a leader in non-invasive hemodynamic monitoring, has announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock

Vertos Medical Secures $28m in Latest Round of Funding

Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.

VitalConnect Announces Closure of $33m Series C Financing

VitalConnect, a leader in medical-grade wearable biosensor systems, has announced that it has closed a Series C Preferred Stock equity financing round of $33 million led by new investors MVM Life Science Partners and Baxter.

Providence Medical Technology announces new equity financing of $10.5 million

Providence Medical Technology, Inc., an innovator in tissue-sparing, cervical-fusion technology, has announced the closing of $10.5 million in new equity financing for the company.

Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease

Wilson Therapeutics AB has announced that the Phase II study of WTX101 (bis-choline tetrathiomolybdate; Decuperate®), an investigational first in class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease, met its primary endpoint.

MVM invests €15.2m in Valneva SE

Valneva SE is a commercial stage vaccine company with products to prevent Japanese encephalitis and cholera